Literature DB >> 15548261

The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection.

O Wald1, O Pappo, Z B Ari, E Azzaria, I D Wiess, I Gafnovitch, H Wald, U Spengler, E Galun, A Peled.   

Abstract

CCR5Delta32 is a deletion mutation in the chemokine receptor CCR5. Liver inflammatory activity was found to be significantly reduced (P = 0.005) in Jewish Israeli patients infected with the hepatitis C virus (HCV) carrying the CCR5Delta32 allele. The CCR5Delta32 allele does not alter susceptibility to HCV infection; however, it may play a role in the progression and outcome of the disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15548261     DOI： 10.1111/j.1365-2370.2004.00482.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN： 0960-7420


  10 in total

1.  CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.

Authors:  Ankur Goyal; P V Suneetha; G T Kumar; Deepak K Shukla; Naveen Arora; Shiv K Sarin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 2.  Stem cell-based therapies for HIV/AIDS.

Authors:  Olivier Pernet; Swati Seth Yadav; Dong Sung An
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

3.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

Review 4.  Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection.

Authors:  Juan R Larrubia; Selma Benito-Martínez; Miryam Calvino; Eduardo Sanz-de-Villalobos; Trinidad Parra-Cid
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

Review 5.  The role of CCR5 in HCV infection.

Authors:  Martin Coenen; Jacob Nattermann
Journal:  Eur J Med Res       Date:  2010-03-30       Impact factor: 2.175

6.  Role of host genetic factors in the outcome of hepatitis C virus infection.

Authors:  Bertram Bengsch; Robert Thimme; Hubert E Blum
Journal:  Viruses       Date:  2009-08-05       Impact factor: 5.818

7.  Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.

Authors:  Abdulkerim Yilmaz; Hakan Alagozlu; Ozturk Ozdemir; Sema Arici
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

Review 8.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

Review 9.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

10.  CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Authors:  Jason T Blackard; Ling Kong; Susan D Rouster; Rebekah Karns; Paul S Horn; Shyam Kottilil; M Tarek Shata; Kenneth E Sherman
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.